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Abstract. The objective of the present study was to compare 
sex hormone-binding globulin (SHBG) levels according to sex 
(healthy male and female volunteers) and age to determine 
reference values. Serum SHBG expression levels in patients 
with breast cancer with different tumor burden states were 
also determined. A total of 109 samples were obtained from 
34 patients in 3 different disease states (non-tumor, localized 
tumor and systemic metastasis) during follow-up. A sandwich 
ELISA was conducted to measure SHBG, cancer antigen 
(CA)15-3 and CA125 expression levels. Wilcoxon rank-sum 
tests were performed on non-normally distributed data and 
an unpaired t-test was used for normally distributed variables. 
SHBG expression levels were higher in females compared 
with males (P<0.0001). When SHBG expression levels were 
compared by sex, the difference was maintained in the age 
groups <30, 30‑39 and ≥50 years, but not in the 40‑49 years 
group. In males, SHBG expression levels increased until the 
age of 49 and then decreased (P=0.01). In females, SHBG 
expression levels exhibited a decreased trend until the age 
of 49 (P=0.66). In patients with breast cancer, the SHBG 
expression levels revealed a decreasing trend after the age of 
50, which was different compared with the healthy females. 
There was a decreasing trend of SHBG expression levels from 
pre-menopause to post-menopause healthy volunteers (P=0.74). 
CA15-3 (r2=0.07; P=0.59) and CA 125 (r2=-0.18; P=0.17) levels 
did not exhibit any significant correlation with SHBG expres-
sion levels. There was a significant difference in the SHBG 
expression levels between male and female healthy volunteers. 
SHBG expression levels also revealed different patterns 
between healthy female volunteers and female patients with 
breast cancer ≥50 years of age. The present study demonstrated 
that SHBG does not have value as a biomarker, but different 
reference values according to age and sex may aid in predicting 
high-risk groups for hormone-dependent cancer and guide 
treatment direction for post-menopausal breast cancer.
Introduction
Sex hormone-binding globulin (SHBG) is a circulating glyco-
protein composed of 373 amino acids and 3 carbohydrate chains 
that can bind to dihydrotestosterone, testosterone and estra-
diol, especially C18 or C19 and 17-β-hydroxyl groups. SHBG 
regulates plasma clearance and the uptake of sex hormones (1). 
High SHBG expression levels theoretically decrease the 
uptake of sex hormones. Notably, only a small percentage 
(<2%) of steroids are unbound in plasma, and the remainder 
are primarily bound to SHBG and albumin (2). Therefore, 
SHBG may influence the carcinogenesis and progression of 
hormone-dependent types of cancer, such as prostate, ovary 
and breast cancer (3‑5). There are conflicting reports regarding 
the association between serum levels of SHBG and the risk 
of prostate cancer development (3,4). Grasso et al (5) identi-
fied that the plasma SHBG expression levels in patients with 
prostate cancer were higher compared with those with benign 
hyperplasia or healthy volunteers. Moreover, circulating SHBG 
expression levels are higher in patients with lymph node inva-
sion (6) and poor differentiation (7). In a previous prospective 
study of lung cancer development, there were no significant 
difference in the mean concentration of sex hormones or 
SHBG between patients who had lung cancer and those who 
did not have lung cancer (8). However, another previous study 
identified that SHBG concentration was also higher in patients 
with lung cancer (9).
Intracellular SHBG has been reported in liver, placenta, 
endometrial, breast and prostate cancers (7-10). Steroid-free 
SHBG can bind to the cell membrane and once bound, SHBG 
can bind to steroids with equal affinity as it does in the serum. 
This interaction is closely associated with estrogen sensitivity 
to each cell (11). Binding of estradiol to SHBG ultimately 
results in breast cancer cell apoptosis and growth suppression. 
Therefore, SHBG serves a protective role in the exposure of 
breast cells to estrogen (12).
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The SHBG expression levels in healthy postmenopausal 
females has been reported to be lower compared with premeno-
pausal females, although the difference was not statistically 
significant (13). In patients aged 50-64 years, a decline of 
10% was observed in SHBG expression levels compared with 
premenopausal females (14). In patients aged >65 years, SHBG 
expression levels returned to the pre-menopause level (14). 
SHBG expression levels were lower in patients with breast 
cancer compared with in controls (15). In pre-menopausal 
patients with breast cancer, the SHBG binding capacity is in 
the normal range; however, it is decreased in post-menopausal 
patients with breast cancer (16-18). The free fraction of estra-
diol is increased while SHBG exhibits relative or absolute 
decrement in post-menopausal patients with breast cancer (19). 
It has been suggested that different critical expression levels of 
SHBG must be determined for pre-menopause and post-meno-
pausal females because the mean SHBG expression levels in 
these two groups differ (20). Murayama et al (20) identified 
that plasma expression levels of SHBG in postmenopausal 
patients with ER-positive breast cancer are higher compared 
with patients with ER-negative breast cancer. On the contrary, 
there was a considerable overlap of plasma SHBG expression 
levels between patients with estrogen receptor (ER)+ and ER- 
endometrial and cervical cancer (13). The major beneficial 
effect of tamoxifen is that it can block estrogen at the receptor 
level and decrease the level of biologically active estradiol 
by upregulating SHBG expression (21). However, there was 
no significant association between SHBG expression level 
and treatment response in patients with breast cancer (22,23). 
Lymph node metastasis and histological status in patients with 
high SHBG expression levels are similar to patients with low 
SHBG expression levels (24). The recurrence rate between 
high‑ and low‑SHBG expression level groups was not signifi-
cantly different and although the high SHBG group had longer 
disease‑free survival times, this difference was not significant 
in premenopausal patients with breast cancer (20).
In the present study, SHBG reference range was deter-
mined based on sex and age (by decade) of healthy male and 
female volunteers. The serum SHBG expression levels of 
breast cancer exhibited a different trend compared to healthy 
female volunteers by age decade comparison.
Patients and methods
Collection of blood specimens. Peripheral blood samples were 
obtained from healthy volunteers (40 males and 40 females) at 
Inha University Hospital (Incheon, Republic of Korea) subse-
quent to obtaining approval, if no laboratory (routine blood test, 
liver function test and tumor markers) and imaging (plain X-ray 
and CT scan) abnormalities were observed during the regular 
medical check-up. Blood samples from 34 female patients with 
breast cancer were obtained at 109 different time points and 
grouped as follow: i) Group A, non-tumor state after surgery 
(n=37); ii) Group B, localized tumor at diagnosis and during 
pre-operative chemotherapy (n=32); and iii) Group C, systemic 
metastasis (n=40) (Fig. 1). Patients with locally advanced breast 
cancers with clinical stage III with normal laboratory findings 
planned for pre-operative chemotherapy were enrolled. The 
median age was 40 years (range, 25-66 years) for the 40 healthy 
males, 34 years (range, 21-56 years) for the 40 healthy female 
volunteers and 45 years (range, 32-65 years) for the 34 female 
patients with breast cancer. Median follow-up duration was 
14 months (range 2-48 months). The blood samples were 
stored at ‑80˚C. Heparinized vacuum tubes and needles (BD 
Biosciences) were used to avoid platelet damage and venous 
occlusion, as in the clinical setting.
Determination of the normal range of serum SHBG. With 
40 healthy male and 40 healthy female volunteer blood samples, 
the normal cut‑off expression levels of SHBG were defined as 
the mean ±2 standard deviations (21-69 nmol/l) (25). Serum 
SHBG expression levels were considered positive when SHBG 
expression levels were out of this reference range (>69 nmol/l, 
elevated; <21 nmol/l, decreased). Patients aged ≥50 years were 
defined as post‑menopause (26).
ELISA. A sandwich ELISA was performed to measure 
SHBG, cancer antigen (CA)15-3 and CA125 expression levels 
according to the manufacturer's instructions. Goat polyclonal 
antibody kit specific for SHBG (cat. no. M‑0700; 1:50; Alpha 
Diagnostic Intl., Inc.) and monoclonal antibody kits specific 
for CA15-3 (cat. no. IS-F3329; 1:100; LifeSpan Biosciences, 
Inc.) and CA125 (cat. no. CA239T; 1:100; Calbiotech, Inc.) 
were used to coat 96-well microplates. Each blood sample was 
added to the plate and incubated for 1 h at room temperature. 
Following washing 3 times with wash buffer from the kit to 
remove unbound proteins, enzyme-linked antibodies in each 
kit specific for SHBG, CA15‑3 and CA125 were added to wells 
and incubated for 1 h at room temperature and the absorbance 
was measured at 450 nm. A standard curve was constructed 
by plotting absorbance values versus SHBG, CA15-3 and 
CA125 concentrations of the standards. Concentrations in the 
test samples were determined using this standard curve. All 
samples were run in triplicate. The detection limit of SHBG 
was 0.2 nmol/l. Intra- and inter-assay variations of SHBG were 
4.3-8.5 and 7.3-11.5%, respectively. The dilution linearity was 
102% (range 96-108%). The upper normal range was 25 IU/ml 
for CA15-3 and 35 IU/ml for CA125.
Statistical analysis. The data were presented as mean ± stan-
dard deviation. The Shapiro-Wilk test was performed to 
determine whether variables were normally distributed or not. 
An independent t-test was used to compare differences between 
two groups when variables were normally distributed, while 
Wilcoxon rank-sum tests were performed for non-normally 
distributed variables. One-way analysis of variance (ANOVA) 
with Bonferroni post-hoc analysis was used to examine differ-
ences for normally distributed variables among three groups or 
more. If the normality assumption was violated, Kruskal-Wallis 
with Dunn's post-hoc test was performed instead. The correla-
tion between variables was estimated using Spearman's rank 
correlation coefficient. P<0.05 was considered to indicate a 
statistically significant difference. All statistical analyses and 
graphing were performed using SAS software version 9.4 (SAS 
Institute, Inc., Cary, NC, USA) and R version 3.6.1. (27,28).
Results
Healthy volunteers and patients with breast cancer. The 
median age of healthy female volunteers was younger 
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compared with healthy males (P=0.027) or patients with 
breast cancer (P<0.001; Fig. 2). A total of 109 samples were 
obtained from patients with breast cancer in 3 different 
disease states (Group A, non-tumor state after surgery, n=37; 
Group B, localized tumor at diagnosis and during neo-adjuvant 
chemotherapy, n=32; and Group C, systemic metastasis, n=40) 
during a long-term follow-up (Fig. 1).
Comparison of SHBG expression levels with sex and age 
in healthy volunteers. The mean expression levels of SHBG 
Figure 1. Different time points when blood was collected for sex hormone-binding globulin measurement during breast cancer progression with different 
tumor burden. (Group A) Cancer-free state with neo-adjuvant chemotherapy and surgery. (Group B) Initial diagnosis state of locally advance breast cancer. 
(Group C) High tumor burden state with systemic relapse after surgery.
Figure 2. Age distribution of healthy males, healthy females and patients with breast cancer. Age, mean ± standard deviation.
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in male and female healthy volunteers were 29.0±11.6 and 
46.4±12.8 nmol/l, respectively. The SHBG expression levels 
were significantly higher in females compared with males 
(P<0.0001; Fig. 3A). The difference in SHBG expression levels 
due to sex was compared in healthy volunteer subgroups strati-
fied by age; the difference between sexes was maintained in 
people aged <30, 30‑39 and ≥50 years, but not in the age group 
of 40-49 years (Fig. 3B) (Table I). In men, SHBG expression 
levels increased until the age of 49 and then decreased (P=0.01). 
In females, SHBG expression levels decreased until the age of 
49. An increasing pattern in females ≥50 years was identified, 
which was not a statistically significant difference (P=0.66; 
Figure 3. Comparison of SHBG expression levels in healthy volunteers and patients with breast cancer. SHBG expression levels presented by: (A) Sex (healthy 
females, healthy males and total healthy females and males); (B) age by decade in both healthy females and healthy males; (C) pre- and post-menopausal states 
of healthy females; and (D) patients with breast cancer in different cancer group with different tumor burden. SHBG, sex hormone-binding globulin.
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Fig. 3B) (Table I). In females, there was no significant differ-
ence in the SHBG expression levels between the pre-menopause 
group <50 years and the post‑menopause group ≥50 years 
(46.2±13.2 vs. 48.3±8.8 nmol/l; P=0.74; Table II) (Fig. 3C).
Figure 4. Comparison of SHBG expression levels in patients with breast cancer by (A) total patients by age decade, (B) by age in each cancer group with 
different tumor burden and (C) by menopause state in each cancer group with different tumor burden. Boxplots with maximum and minimum values. Bar 
represents the median value and dots are outliers. SHBG, sex hormone binding-globulin. 
Table I. Comparison of SHBG levels by sex and age in healthy volunteers.
 Male Female
 ---------------------------------------------------------------------------- ---------------------------------------------------------------------------
 Serum SHBG level,  Serum SHBG level
Age (years) mean ± SD Patients, n mean ± SD Patients, n P-value
Range 29.0±11.6 40 46.4±12.8 40 <0.0001a
<30 20.8±5.1 7 51.2±17.0 11 0.0008b
30-39 25.6±7.9 12 44.4±11.3 15 <0.0001a
40-49 36.6±13.1 13 43.8±10.8 11 0.17b
≥50 28.9±11.7 8 48.3±8.8 3 0.05b
P-value  0.01c  0.66c
Data were analyzed using an aIndependent t-test, a bWilcoxon rank sum test and a cKruskal-Wallis test. SHBG, sex hormone binding-globulin; 
SD, standard deviation.
Table II. Comparison of SHBG levels by menopause state in female healthy volunteers.
 Serum SHBG level, mean ± SD Participants, n P-value
Pre-menopause (<50 years) 46.3±13.2 37 
Post‑menopause (≥50 years) 48.3±8.8 3 0.74a
SHBG, sex hormone binding-globulin; SD, standard deviation; aKruskal-Wallis test.
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SHBG expression levels in patients with breast cancer. 
Although there was a trend of increasing SHBG expression 
levels with larger tumor volumes, there was no statistically 
significant difference (P=0.86) in the SHBG expression 
levels between the 3 different tumor states: Group A (n=37), 
47.3±23.7 nmol/l; Group B (n=32), 49.1±32.2 nmol/l; and 
Group C (n=40), 51.4±29.0 nmol/l (Fig. 3D). SHBG expres-
sion levels were compared by age in patients with breast 
cancer regardless of cancer state, and these levels exhibited a 
decreasing trend which revealed an increasing trend in healthy 
females (Fig. 4A). SHBG expression levels were compared by 
age between the 3 groups; there was no significant difference 
in Group A by age; however, Groups B and C exhibited a 
decrease in expression in the ≥50 years groups (Fig. 4B). SHBG 
expression levels were compared between pre-menopause and 
post-menopause groups; the SHBG expression level exhibited 
a decreasing trend in post-menopausal patients compared 
with pre-menopausal patients, in all three groups (Table III; 
Fig. 4C).
Comparison of serum SHBG positivity in each decade of age 
in breast cancer. Using a cut-off point of the mean ±2 standard 
deviations for SHBG positivity, a sensitivity of 36%, a speci-
ficity of 65% and an accuracy of 46% were identified. For the 
pre‑menopause group, the sensitivity, specificity and accuracy 
were 44, 60 and 50%, respectively. In the post-menopause 
group, the sensitivity, specificity and accuracy were 26, 71 
and 42%, respectively. When the sensitivity and specificity 
in each decade were evaluated in whole breast cancers, the 
sensitivity and specificity were as follows: 35 and 54% for age 
30-39 years; 52 and 71% for age 40-49 years; and 26 and 71% 
for age ≥50 years, respectively (Table IV).
Comparison of serum positivity among SHBG, CA15‑3 
and CA125 in breast cancer. In 109 samples with different 
states of breast cancer, sensitivity, specificity and accuracy of 
Table IV. Comparison of SHBG positivity in each decade of 
age in breast cancer.
Biomarker Sensitivity, % Specificity, % Accuracy, %
Total (n=109) 36 65 46
30-39 (n=33) 35 54 42
40-49 (n=28) 52 71 57
≥50 (n=48) 26 71 42
Pre-menopause 44 60 50
(n=61)
Post-menopause 26 71 42
(n=48)
Table V. Comparison of sensitivity, specificity and accuracy of 
3 biomarkers in breast cancer.
Biomarker Sensitivity, % Specificity, % Accuracy, %
CA15-3 61 82 68
CA125 51 65 56
CA15-3 and 75 59 70
CA125
CA15-3, CA125 79 32 64
and SHBG
Table III. Comparison of SHBG levels by age in different cancer states.
 Group A Group B Group C
 ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
 Serum SHBG  Serum SHBG  Serum SHBG  
Parameter (mean ± SD) Samples, n (mean ± SD) Samples, n (mean ± SD) Samples, n P-value
A, age (years)
All patients 47.3±23.7 37 49.1±32.2 32 51.4±29.0 40 0.86a
30-39 49.5±25.4 13 51.9±24.2 11 49.9±23.0 9 0.97b
40-49 53.3±28.0 7 57.9±48.2 7 51.9±32.0 14 0.85a
≥50 43.2±21.0 17 42.4±29.1 14 51.8±30.9 17 0.55b
P-value 0.72a  0.59a  0.94a  
B, menopause state
Pre-menopause 50.8±25.7 20 54.3±34.2 18 51.1±28.3 23 0.98a
Post-menopause 43.2±21.0 17 42.4±29.1 14 51.8±30.9 17 
P-value 0.33c  0.33d  0.93d  0.62
Data were analyzed using a aKruskal-Wallis test, bANOVA, an cIndependent t-test and a dWilcoxon rank sum test. SHBG, sex hormone binding-
globulin; SD, standard deviation.
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CA15-3 and CA125 were simultaneously compared (Table V). 
Sensitivity increased when considering CA15-3 and CA125 
together (75%). The highest sensitivity (79%) was obtained 
when all three markers were used. When SHBG was measured 
alongside CA15‑3 or CA125 (64%), no benefit was identified 
regarding accuracy with CA15-3 or CA125 (70%) (Table V). 
CA15-3 and CA125 levels were moderately correlated with 
each other (r2=0.54; P<0.0001; data not shown). However, 
both CA15-3 (r2=0.07; P=0.59) and CA125 (r2=-0.18; P= 0.17) 
serum levels were not significantly correlated with SHBG 
(Fig. 5A and B, respectively).
Discussion
SHBG is a circulating glycoprotein that binds dihydrotestos-
terone, testosterone and estradiol; notably, its highest binding 
affinity is for dihydrotestosterone and testosterone, with a 
lower affinity for estradiol (1). As a result, an increase in SHBG 
serum concentration may result in lowering the percentage of 
unbound dihydrotestosterone, testosterone and estradiol (2). 
Therefore, SHBG may be a useful predictor of circulating 
total and bioavailable sex hormone levels (2). By contrast to 
healthy females, to the best of our knowledge, there has been 
no analysis of the SHBG expression levels in healthy males. As 
revealed by the present data, although there was a difference 
in age distribution of male to female volunteers, healthy males 
exhibited a lower range of SHBG expression levels compared 
with healthy females by age (decade of age). This indicates that 
different normal reference values of SHBG expression levels 
for males and females are needed to determine abnormal 
expression levels of SHBG for risk evaluation of cancer or 
for cancer status prediction. In males, the SHBG expression 
levels increased from 30 to 49 years of age and then decreased 
≥50 years, at which age the incidence of prostate cancer typi-
cally increases (3). This pattern was reversed in females who 
exhibited a decreasing trend until 49 years. SHBG expression 
levels increased in patients aged >50 years, when the incidence 
of breast cancer typically increases (15,23).
There is controversy regarding the association between 
the serum levels of SHBG and the risk of prostate cancer 
development, which may come from fixed normal reference 
value regardless of sex and age. In a Japanese population, 
SHBG expression levels were not strongly associated with 
the risk of prostate cancer, except in males age <60 years (3). 
However, a previous study in Spain identified that low 
bioavailability of testosterone levels and high SHBG expres-
sion levels were associated with a 4.9- and 3.2-fold increase 
in the risk of prostate cancer, respectively (4). In localized 
prostate cancer, the preoperative serum SHBG expression 
levels were associated with prostatic extension and Gleason 
score (29). SHBG was not considered a biomarker for 
high-grade disease (30). For future prostate cancer studies, 
normal reference values of SHBG should reflect sex and age. 
In lung cancer which is non-endocrine cancer, the typical 
negative correlation between SHBG expression levels and 
total dihydrotestosterone observed in healthy volunteers 
and other endocrinological gynecology cancer was reversed, 
perhaps due to the systemic manifestation of thyrotoxicosis, 
chronic liver disease and disseminated cancer associated 
with liver metastasis (8,9). In patients with cancer, different 
reference ranges by age, sex, cancer type (endocrinological 
versus non-endocrinological) and cancer stage (localized 
versus systemic manifestations) can be applied to clarify 
these controversial clinical results.
A previous study demonstrated that SHBG expression 
levels are higher in the first 12 days of luteal phase compared 
with the rest of the menstrual cycle (31,32). In both pre-meno-
pause and post-menopause groups, SHBG expression levels 
Figure 5. Correlation between SHBG and (A) CA15-3 or (B) CA125. SHBG, 
sex hormone binding-globulin; CA, cancer antigen. 
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decreased with increasing weight. SHBG level was lower in 
single nulliparous compared with married nulliparous or 
parous females (31). In post-menopause, SHBG increased in 
the years following menopause (31). In the present study of 
healthy volunteers, a similar trend was revealed as SHBG 
expression levels exhibited a decreasing trend until age 49 
and then an increasing pattern >50 years. Therefore, it was 
suggested that the SHBG expression levels must be deter-
mined for pre-menopausal and post-menopausal females 
separately, as the mean SHBG expression levels in these two 
groups were different (20). Serum SHBG expression levels 
are regulated by a biologically active and unbound hormone 
fraction, with androgens having an inhibitory effect and 
estrogens having a stimulatory effect on the SHBG expres-
sion levels (1,16,33). High SHBG expression levels were 
significantly associated with decreased breast cancer risk 
and protective function in post-menopausal females (34). In 
the present study, in patients with breast cancer in Groups B 
and C, the SHBG expression levels indicated a decreasing 
trend after age 50, although it showed an increasing trend 
in healthy females aged ≥50 years. Although the patients in 
this study were mostly younger than Western patients (35), 
receiving mainly chemotherapy instead of hormonal treat-
ment and the healthy volunteers were younger than the 
patients with cancer, the trend was similar to that in Western 
patients when the SHBG expression levels was compared 
by age (14,15). SHBG expression levels were increased 
by estrogen but decreased by testosterone, suggesting that 
upregulated SHBG may be an indicator of an estrogenic 
environment (11). Therefore, it was suggested that SHBG 
expression levels were an improved predictor of hormone 
treatment compared with the estrogen receptor, as higher 
SHBG expression levels were identified in ER+ patients 
compared with ER- patients (20,33,36). Notably, the SHBG 
expression levels in postmenopausal patients with ER+ were 
higher compared with patients with ER- endometrial and 
cervical cancer, even if the SHBG level revealed a high 
overlapping range between ER+ and ER- groups (1). Whether 
the considerable overlap of SHBG expression levels between 
ER+ and ER- gynecological cancer is due to other factors, 
such as heterogeneity of tumor stage, varying degree of 
illness or weight, needs to be studied in the future (13).
A novel biomarker should be an independent predictor 
of the selected outcome; it must increase the multivariable 
predictive accuracy of a model (24). Despite controversy 
surrounding the correlation of SHBG with ER status, 
suggesting that plasma SHBG has little value as a predictive 
index in breast cancer, Dimou et al (37) recently reported a 
potentially causal inverse association between SHBG expres-
sion levels and risk of ER positive breast cancer. In the present 
study, although specificity was good ≥50, the sensitivity was 
too low in patients with breast cancer to confirm the role of 
SHBG as a tumor suppressor. SHBG expression levels were 
not correlated with known tumor markers CA15-3 or CA125. 
No additive effect of the biomarkers was identified using 
all three biomarkers for cancer prediction. A larger study 
using an age‑specific reference value with estrogen level may 
resolve this issue in the future. A non-synonymous single 
nucleotide polymorphism in exon 8 can result in an amino 
acid substitution of asparaginase for aspartic acid (D356N, 
rs6259) in the SHBG protein (38). The asparagine allele of 
SHBG was associated with elevated circulating SHBG in 
postmenopausal females (38). This genotype may be applied 
in future studies as a biomarker.
Genistein not only increases SHBG expression in Hep-G2 
cells, but also suppresses Hep-G2 cell proliferation (2). As 
genistein is an inhibitor of tyrosine‑specific protein kinases, 
isoflavonoid may serve a role in the prevention of malignant 
tumors, including hormone-dependent cancers in countries 
with high consumption of soy products, such as Japan and 
Korea (2). Genotyping and diet analysis must be combined in 
the future to determine the protective role of SHBG in female 
breast and gynecological cancer.
In conclusion, there was a significant difference in the 
SHBG expression levels between male and female healthy 
volunteers. There was also a different pattern in the SHBG 
expression levels between female healthy volunteers and 
female patients with breast cancer ≥50 years. Although SHBG 
itself cannot be used as a biomarker, different reference values 
stratified by age and sex may help to determine its role in 
predicting a high-risk group for hormone-dependent cancer, 
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